Jessica Fees is CFO at Surface Oncology, Inc. (SURF). They have made 3 open-market trades across 1 company since 2021, most recently 2023-09-08.
CIK 0001760391
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SURF | 101,915 | $109K |
Shares reported on the most recent Form 4, priced at the 2023-08-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SURF | SELL | 2023-08-01 | 2023-08-11 | $0.94 | $9K | +3.0% | N/A | N/A |
| SURF | SELL | 2022-08-03 | 2022-08-05 | $1.72 | $10K | -1.1% | -25.7% | -31.3% |
| SURF | SELL | 2021-07-21 | 2022-01-14 | $6.10 | $242K | -18.5% | -16.4% | -39.6% |
| SURF | SELL · 10b5-1 | 2021-02-08 | 2021-02-09 | $12.45 | $19K | -27.0% | -27.7% | -37.9% |
| SURF | SELL · 10b5-1 | 2021-02-01 | 2021-02-03 | $11.19 | $17K | +2.9% | -29.9% | -34.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.